Results 171 to 180 of about 8,362,360 (307)

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Catalytic hydroboration of aldehydes with electron-rich alkoxysilylenes: from mechanistic insights to highly active catalysts. [PDF]

Chem Sci
Kapp L, Schmetten B, Wölper C, Haberhauer G, Schulz S.   +4 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Exercise-Associated Risk After Spontaneous Coronary Artery Dissection: Implications From Highly Active Patients. [PDF]

JACC Adv
Skalidis I, Jelisejevas J, Cioffi GM, Cook S, Togni M.   +4 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Creating highly active fluoroacetate dehalogenases via gate-based synergetic chain design. [PDF]

Nat Commun
Wang CZ, Huang H, Hu Z, Gao L, Lin ZQ, Shi M, Song Z, Li M, Wang Y, Chen KW, Liu Y, Ma Y, Chen B, Yan Q, Zhang ZM, Wang JB.   +15 more
europepmc   +1 more source

Bourolong [i.e. Boorolong] Station, New South Wales, ca. 1848 [picture] /

Title from inscription on verso.; Rex Nan Kivell Collection NK 671/3.; Inscription; "Bourolong" -- In ink below image. "Bourolong ; Chas. Marsh Esq." --In index.; In: Views in New South Wales, Australia, ca.
Thomson, Edward, active 1840-1870.
core  

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Expression of Concern for "Highly Active Biphasic Anatase-Rutile Ni-Pd/TNPs Nanocatalyst for the Reforming and Cracking Reactions of Microplastic Waste Dissolved in Phenol". [PDF]

ACS Omega
Nabgan W, Nabgan B, Tuan Abdullah TA, Ikram M, Jadhav AH, Jalil AA, Ali MW.   +6 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source